UK biotech Epsilogen has bought US-based TigaTx, pooling their resources to create what it says will be a leader in ...

Converging computational and laboratory technologies are helping anti-cancer immune responses hit their target more effectively.

J&J exhibited additional findings from the Vivacity-MG3 study, displaying that nipocalimab met its key secondary endpoint.

Antiphospholipid Antibody Syndrome APS is an autoimmune condition where the immune system of the body mistakenly forms ...

Epsilogen completes acquisition of TigaTx to create world’s leading pan-isotype cancer antibody company: London Tuesday, April 8, 2025, 10:00 Hrs [IST] Epsilogen, the global lea ...

With a rising measles outbreak in the U.S., experts stress the importance of vaccination. While most individuals are ...

U.K.-based Epsilogen has bought Boston biotech TigaTx with the aim of creating “the world’s leading pan-isotype cancer ...

Epsilogen has acquired antibody developer TigaTx in a deal that collates work from the companies’ alternative antibody ...

HER2 is responsible for cancer growth and is the target of existing therapies, such as the most commonly used type of antibodies, IgG. However, this treatment is not always effective in some patients.

Johnson & Johnson reports long-term efficacy and steroid-sparing benefits of nipocalimab in antibody-positive generalized ...